Joanna Opalinska

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · The Lancet Oncology · 2019 · 796 citations

Medicine, Pharmacology, Pharmacotherapy +11

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat et al. · The Lancet Oncology · 2018 · 244 citations

Medicine, Oncology, Pharmacotherapy +16

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat et al. · Blood Cancer Journal · 2019 · 213 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Asim V. Farooq, Simona Degli Esposti, Rakesh Popat et al. · Ophthalmology and Therapy · 2020 · 176 citations · Full text

Medicine, Oncology, Pharmacology +15

Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis

Héctor M. Álvarez, Joanna Opalinska, Li Zhou et al. · PLoS Genetics · 2011 · 145 citations · Full text

Life Sciences, Genetics, Oncology +17